

## **PHESGO or PERJETA + Herceptin®** (trastuzumab) may be an option for you

**PHESGO®**  
pertuzumab/trastuzumab/hyaluronidase-zzxf  
SUBCUTANEOUS INJECTION / 1,200 mg/500 mg/30,000 units  
600 mg/500 mg/20,000 units

**PERJETA®**  
pertuzumab  
420 mg INJECTION FOR INTRAVENOUS USE

### *Potential HER2+ early breast cancer treatment experience with PHESGO or PERJETA + Herceptin before and after surgery*

**Diagnosed with HER2+ early breast cancer  
that has a high chance of coming back**



#### **Treatment before surgery (neoadjuvant treatment)**

Start on PHESGO or PERJETA + Herceptin, plus chemotherapy, for 3-6 cycles (9-18 weeks)\*



#### **Surgery after treatment**

#### **Possible result of surgery: No cancer cells found**

This is called a pathologic complete response (pCR)



#### **Treatment after surgery (adjuvant treatment)**

Continue receiving PHESGO or PERJETA +  
Herceptin every 3 weeks for the remaining  
12-15 cycles (36-45 weeks) of treatment\*



***This could be  
your next step.***

\*PHESGO or PERJETA + Herceptin is given for a total of 18 cycles, unless the cancer comes back or side effects cause the treatment to be stopped sooner. You will also get chemotherapy, but the dosing schedule and number of cycles will depend on which type of chemotherapy you are getting. Chemotherapy is typically stopped sooner than targeted treatment. Your doctor will decide what chemotherapy regimen is right for you.



**Get questions to ask your doctor  
on the next page.**

### **What does PHESGO treat?**

PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for:

- use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PHESGO should be used as part of a complete treatment regimen for early breast cancer.
- use after surgery (adjuvant treatment) in adults with HER2-positive early breast cancer that has a high likelihood of coming back.

### **Important Safety Information**

#### **What are the most serious side effects of PHESGO?**

- PHESGO may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure)
- Receiving PHESGO during pregnancy can result in the death of an unborn baby and birth defects
- PHESGO may cause serious lung problems

Please see additional Important Safety Information throughout, and full Prescribing Information, including most serious side effects, for [PHESGO](#) and [PERJETA](#).

### **What does PERJETA treat?**

PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:

- use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer.
- use after surgery (adjuvant treatment) in people with HER2-positive early breast cancer that has a high likelihood of coming back.

### **Important Safety Information**

#### **What are the most serious side effects of PERJETA?**

- PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure)
- Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects

**HER2<sup>+</sup>  
empowered**

## Start the conversation

Bring these questions to your doctor or nurse to learn more about PHESGO or PERJETA + Herceptin® (trastuzumab) and about what to expect next.

- ☐ Is continued treatment with PHESGO or PERJETA + Herceptin right for me?
- ☐ What can I expect during adjuvant treatment with PHESGO or PERJETA + Herceptin?
- ☐ How are PHESGO and PERJETA + Herceptin different from each other?
- ☐ Do I take PHESGO or PERJETA + Herceptin with chemotherapy?
- ☐ What potential side effects should I expect or know about?
- ☐ When will I start treatment?
- ☐ How long will I get PHESGO or PERJETA + Herceptin?
- ☐ How long will I get chemotherapy?
- ☐ How will you know if my treatment is working?
- ☐ Can I switch from PERJETA + Herceptin to PHESGO, either at the start of adjuvant treatment or later on?
- ☐ I have a pCR. Why do I need more treatment?

### Important Safety Information (cont'd)

#### What are the most serious side effects of PHESGO?

**PHESGO may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).**

- The risk for and seriousness of these heart problems are highest in people who received both PHESGO and a certain type of chemotherapy (anthracycline)
- Your doctor will check for signs of heart problems before, during, and after treatment with PHESGO. Based on test results, your doctor may hold or discontinue treatment with PHESGO
- Contact a healthcare professional immediately for any of the following: new onset or worsening shortness of breath, cough, swelling of the ankles/legs, swelling of the face, palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness

**Receiving PHESGO during pregnancy can result in the death of an unborn baby and birth defects.**

- Birth control should be used while receiving PHESGO and for 7 months after your last dose of PHESGO. If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping PHESGO
- If you think you may be pregnant, you should contact your healthcare provider immediately
- If you are exposed to PHESGO during pregnancy, or become pregnant while receiving PHESGO or within 7 months following the last dose of PHESGO, you are encouraged to report PHESGO exposure to Genentech at 1-888-835-2555

### Important Safety Information (cont'd)

#### What are the most serious side effects of PERJETA?

**PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).**

- Your doctor may run tests to monitor your heart function before and during treatment with PERJETA
- Based on test results, your doctor may hold or discontinue treatment with PERJETA
- Contact a health care professional immediately for any of the following: new onset or worsening shortness of breath, cough, swelling of the ankles/legs, swelling of the face, palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness

**Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.**

- Birth control should be used while receiving PERJETA and for 7 months after your last dose of PERJETA. If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping PERJETA
- If you think you may be pregnant, you should contact your healthcare provider immediately
- If you are exposed to PERJETA during pregnancy, or become pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA in combination with Herceptin, you are encouraged to report PERJETA exposure to Genentech at 1-888-835-2555

Please see additional Important Safety Information throughout, and full Prescribing Information, including most serious side effects, for **PHESGO** and **PERJETA**.

**HER2<sup>+</sup>**  
**empowered**

**PHESGO®**  
pertuzumab/trastuzumab/hyaluronidase-zzxf  
SUBCUTANEOUS INJECTION / 1,200 mg/600 mg/30,000 units  
400 mg/600 mg/20,000 units

**PERJETA®**  
pertuzumab  
420 mg INJECTION FOR INTRAVENOUS USE

## Important Safety Information (cont'd)

### What are the most serious side effects of PHESGO? (cont'd)

#### PHESGO may cause serious lung problems.

- Your doctor may check for signs of lung problems including:
  - Severe shortness of breath
  - Fluid in or around the lungs
  - Weakening of the valve between the heart and the lungs
  - Not enough oxygen in the body
  - Swelling of the lungs
  - Scarring of the lungs

### Who should not receive PHESGO?

- PHESGO should not be used in patients who are allergic to pertuzumab, trastuzumab, hyaluronidase, or to any of the ingredients in PHESGO

### What are other possible serious side effects?

- **PHESGO may worsen low white blood cell counts caused by chemotherapy:** Low white blood cell counts can be life threatening and were seen more often in patients receiving Herceptin® (trastuzumab) plus chemotherapy than in patients receiving chemotherapy alone. Your doctor may check for signs of low white blood cell counts when he or she examines you
- **PHESGO may cause administration-related reactions:** PHESGO is given as an injection. The active ingredients in PHESGO have been associated with severe administration reactions, including hypersensitivity or anaphylaxis, which can be fatal. Talk to your doctor if you feel any symptoms. The most common symptoms include dizziness, nausea, chills, fever, vomiting, diarrhea, hives, swelling of the skin, breathing problems, or chest pain

### What are the most common side effects?

The most common side effects of PHESGO when given with chemotherapy as part of an early breast cancer regimen are:

- Hair Loss
- Nausea
- Diarrhea
- Low levels of red blood cells
- Weakness

## Important Safety Information (cont'd)

### What are other possible serious side effects?

- PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA
- **Infusion-related reactions:** PERJETA is a medicine that is delivered into a vein through a needle. PERJETA has been associated with infusion-related reactions, some fatal. The most common infusion-related reactions when receiving PERJETA, Herceptin, and docetaxel were feeling tired, abnormal or altered taste, allergic reactions, muscle pain, and vomiting. The most common infusion-related reactions when receiving PERJETA alone were fever, chills, feeling tired, headache, weakness, allergic reactions, and vomiting
- **Severe allergic reactions:** Some people receiving PERJETA may have severe allergic reactions, called *hypersensitivity reactions* or *anaphylaxis*, which may happen quickly and may affect many areas of the body. Severe allergic reactions, some fatal, have been observed in patients treated with PERJETA

### What are the most common side effects?

The most common side effects of PERJETA when given with Herceptin and chemotherapy as part of an early breast cancer regimen before surgery are:

- |   |   |
|---|---|
| • Constipation  | • Low levels of white blood cells with or without fever |
| • Damage to the nerves (numbness, tingling, pain in hands/feet) | • Low platelet count                                    |
| • Diarrhea  | • Mouth blisters or sores                               |
| • Feeling tired   | • Nausea  |
| • Hair loss   | • Pain in the muscles                                   |
| • Headache  | • Vomiting  |
| • Low levels of red blood cells                                 | • Weakness  |

Side effects may vary based on chemotherapy regimen.

The most common side effects of PERJETA when given with Herceptin and chemotherapy as part of an early breast cancer regimen after surgery are:

- |                 |   |
|-----------------|---|
| • Diarrhea      | • Damage to the nerves (numbness, tingling, pain in hands/feet) |
| • Nausea        | • Vomiting  |
| • Hair Loss     |   |
| • Feeling tired |   |

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at **1-800-FDA-1088** or [www.fda.gov/medwatch](http://www.fda.gov/medwatch). You may also report side effects to Genentech at **1-888-835-2555**.

**Talk to a healthcare professional for more information about the benefits and risks of PHESGO and of PERJETA.**

**Please see full Prescribing Information for additional Important Safety Information, including most serious side effects, for [PHESGO](#) and [PERJETA](#).**

If you cannot afford your medication, visit [genentech-access.com/patient](http://genentech-access.com/patient) for financial assistance information.

